Table 1

Characteristics of the included studies

AuthorsStudy designSamplesBNPCut-offMean/median hs-cTnI (non-survivor vs survivor)
(pg/mL)
Male (%)Mean/median Age (years)HTN (%)CAD/CVD (%)Diabetes (%)Respiratory comorbidities (%)
Cao J 2020Observational, Retrospective102 (17/85)NT-pro BNP≥900 pg/mL21.5 (9.4–44.1) vs 7.6 (3.2–11.0) (All)76.5 vs 47.172 vs 5364.7 vs 2017.6 vs 2.4 (CAD)35.3 vs 5.923.5 vs 7.1 (COPD)
Chen 20203 Observational, Retrospective123 (31/92)NT-pro BNPN/A0.21±0.45 vs 0.01±0.01
*troponin T
71 vs 4272 vs 5348.4 vs 38.325.8 vs 7.6 (CAD)19.4 vs 8.79.7 vs 3.3 (COPD)
Chen T 20206 Observational, Retrospective274 (113/161)NT-pro BNP≥285 pg/mL40.8 (14.7–157.8) vs 3.3 (1.9–7.0)73 vs 55)68.0 vs 51.048 vs 2414 vs 4 (CVD)21 vs 1410 vs 4(CLD)
Li K 20209 Observational, Retrospective32 (11/21)NT-pro BNP≥241 pg/mL24.1 (13.0–202.1) vs
4.3 (2.0–10.6)
73 vs 55)57 (69 vs 55)30 (47 vs 28)4 (13 vs 2) (CAD)15 (13 vs 15)2 (7 vs 1) (COPD)
Gao L 2020*12 Observational, Retrospective54NT-pro BNP>88.64 pg/mLN/AN/AN/AN/AN/AN/AN/A
Shi S 2020*5 Observational, Retrospective416NT-pro BNPN/AN/AN/AN/AN/AN/AN/AN/A
  • *Group was not mortality versus no mortality (high NT-proBNP vs low-moderate NT-proBNP; cardiac injury vs no cardiac injury).

  • CAD, coronary artery disease; CLD, Chronic Lung Disease; COVID-19, coronavirus disease 2019; CVD, cardiovascular Disease; HTN, hypertension; N/A, not available; NT-proBNP, N-terminal pro-brain natriuretic peptide.